Blueprint Medicines is collaborating with Roche on the discovery, development and commercialisation of up to five targeted cancer immunotherapies, in a deal potentially worth more than $1 billion.

Affymetrix's board of directors today dismissed the most recent bid by Origin Technologies to acquire Affy for $17.00 per share in an all-cash transaction,

Recently, AES (Advanced Electrophoresis Solutions Ltd.) located in Cambridge, Canada announced that Ms. Mu Yiping will become the executive director & co-CEO

According to GEN website, Regeneron Pharmaceuticals recently had granted Intellia Therapeutics gene editing technology.

Today, GE Ventures and Mayo Clinic announced the launch of Vitruvian Networks, Inc., an independent platform company committed to accelerating

Life science company LGC announced today that it has acquired a majority stake in laboratory automation company Douglas Scientific.

Illumina published in April. 15 that $100 million will be invested to a new asset management company——Illumina Venture.

Organized by Sansure Biotech Inc. , the national demonstration center for genetic testing technology applications has been approved by NDRC and becomes

March 4, Ningbo MedicalSyetem Biotechnology Co., Ltd get the laboratory accreditation certificate of China National Accreditation Service for Conformity Assessment.

Jiangxi Huaxing established on Oct., 2005, is an earliest and largest integrated independent medical laboratory in Jiangxi province.

Financial department of social security deputy director Song Qichao today introduced that in 2016, the fiscal health expenditure budget will reach 1236.3 billion RMB,

Recently, Siemens Healthcare unveiled its new brand name Siemens Healthineers. The new brand underlines Siemens Healthcare's pioneering spirit and its engineering expertise in the healthcare industry.

Editas Medicine announced a three-year, $5 million agreement with Cystic Fibrosis Foundation Therapeutics recently, and Caribou Biosciences completed a $30 million Series B financing round.

Shenzhen Haplox Biotechnology Co., Ltd. is a hi-tech enterprise whom devoted itself into R&D and clinical application in ultromicro tumor genetic inspection,

China’s National Health and Family Planning Commission announced the final list of the first series of the national health insurance negotiation, while the oral targeted drug Erlotinib (Tarceva),